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Introduction
Arterial hypertension is responsible for worldwide
burden due to high cardiovascular morbidity and mor-
tality. In Westernized countries about 40% of adults are
affected by hypertension, responsible for a higher risk
of stroke, acute coronary syndromes, heart failure and
chronic renal disease.1
Although several appropriate and integrated phar-
macological strategies are available, blood pressure
(BP) control still remains largely unsatisfactory. Con-
sidering that uncontrolled hypertension leads to excess
target organ damage and complications,2 the patients
with resistant hypertension (RHT) are still exposed to
an excess risk of cardiovascular disease events.3
RHT is arbitrarily defined when a therapeutic strat-
egy that includes appropriate lifestyle measures plus a
diuretic and two other antihypertensive drugs, belong-
ing to different classes at adequate doses, fails to lower
systolic BP (SBP) and diastolic BP (DBP) values to 140
and 90 mmHg, respectively.4,5
Despite the growing number of clinical studies of
RHT in the past decade, the RHT prevalence has not
been properly examined. Some retrospective studies
have examined the prevalence of RHT in various set-
tings and overall small studies suggesting a prevalence
ranging from around 5% in general practice (with poor
selection of patients) to 50% in high specialized cen-
ters, including patients with chronic kidney disease.6
Among studies performed in larger cohorts examining
the epidemiologic characteristics of RHT, two of these
have included patients firstly evaluated in tertiary hy-
pertension facilities, showing the prevalence from
11% to 21%.7
However, in more than 50% of these patients, one
or more of the various subtypes of refractory hyperten-
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sion are present, including white-coat hypertension (iso-
lated clinic or office hypertension: office BP readings
usually greater than 140/90 mmHg and reliable out-of-
office readings that are routinely less than 140/90
mmHg), pseudo-resistance (lack of adherence and/or
BP poor measurement technique) or secondary hyper-
tension (SH).8
In the present study we sought to systematically in-
vestigate in a large cohort of newly diagnosed hyper-
tensive patients the prevalence of RHT, and evaluate
the presence of some secondary forms of arterial hy-
pertension.
Materials and Methods
Participants
From January 2011 to September 2016, we have
evaluated 3685 consecutive hypertensive patients who
were studied at Departmental Unit of Secondary Hy-
pertension, Department of Internal Medicine and Med-
ical Specialties, La Sapienza University (Rome, Italy),
referred by specialist health care. Informed consent was
obtained from all subjects after the explanation of the
purpose and potential risk of the study. All patients un-
derwent a complete physical examination and labora-
tory exams. Laboratory tests were reported in Table 1.
We performed a screening for SH with the hormones
analysis such as plasma aldosterone (PAC), plasma
renin activity (PRA), serum cortisol (PC), and 24-h
urine excretion for metanephrines, free cortisol (UFC),
aldosterone serum electrolytes and creatinine. Any an-
tihypertensive drug was withdrawn at least 3 weeks (up
to 2 months for spironolactone) before hemodynamic,
biochemical and hormonal evaluation. In patients in
whom treatment could not be withdrawn for ethical rea-
sons, calcium-channel blockers (verapamil) or α-recep-
tor blockers (doxazosin) were allowed at the minimal
doses required to achieve BP control. All patients were
encouraged to adopt lifestyles changes to decrease BP,
for example salt restriction, diet low on saturated
fat/cholesterol, weight reduction, aerobic physical ex-
ercise, limitation of alcohol consumption and smoking
cessation. To exclude white coat hypertension, ambu-
latory blood pressure monitoring (ABPM) and home
BP measurement were performed in addition to the of-
fice BP at the hospital. The physicians instructed pa-
tients to remain adherent to their prescribed
antihypertensive therapy. After an optimization of their
anti-hypertensive therapy, patients were consecutively
reevaluated by a second ABPM. Those patients who
had a normalization of their BP were excluded by the
definition of RHT and defined as pseudoresistant.
Moreover, in all patients we evaluated clinical signs of
sleep disorders with the use of specific questionnaire
(Epworth sleepiness scale).9 Briefly, the patient can sug-
gest the probability of falling asleep (0-3) in 8 different
situations, and a score >10 points represents the proba-
bility of excessive daytime sleepness.9
Ambulatory blood pressure monitoring
ABPM for 24-h was performed by means of oscil-
lometric device Space-Labs 90207 (Space-Labs Med-
ical, Richmond, WA, USA) which was set to measure
BP every 15 min during the day (from 06:00 a.m. to
22:00 p.m.) and every 30 min during the night (from
22.00 p.m. to 06.00 a.m.). The definition of dipper and
non-dipper was established when night time SBP and
DBP measure was >10% and <10% respectively. Sub-
jects without complete 24-h BP measurements (14 di-
urnal and 7 nocturnal) repeated the ABPM. 
Diagnosis of renovascular hypertension
Patients with hyperreninemic aldosteronism under-
went a Doppler-renal-ultrasonography. Doppler renal
artery ultrasonography measurements were performed
using a 3.5 MHZ transducer (Toshiba Aplio XV, Craw-
ley, West Sussex, United Kingdom). The pulsatility
index was calculated, and a side-to-side difference of
>0.20 was used as a criterion for renal artery stenosis.
In addition, evaluation of the blood flow velocity during
early systole was measured, and on acceleration of the
blood flow >3 mm/s2 a criterion for renal artery stenosis
was used. Patients with a positive screening for renal
artery stenosis underwent magnetic resonance imaging
(MRI) or arterial renal angiography. Those patients, di-
agnosed with RVH, and whose renal function was not
irreversibly degraded, with a resistant index less than
0.7, were considered potentially suitable for endovas-
cular revascularization.10
Diagnosis of obstructive sleep apnea
In patients with a positive Epworth sleepiness scale,
a nocturnal polysomnography was performed in our
Hospital, and included the recording of several param-
eters. A 6 h minimum duration was required for diag-
nosis. Data obtained included sleep efficiency, measure
and duration of apnea/hypopnea episodes, apnea/hy-
popnea index (AHI), the number of desaturation greater
than 4% below baseline, and the final diagnosis, ob-
structive sleep apnea syndrome (OSA), was defined as
AHI greater than 5 as all subjects undergoing
polysomnography were symptomatic.11
Diagnosis of primary aldosteronism
Diagnosis of primary aldosteronism (PA) was made
as previously described.12 A cut-off upright PAC/PRA
ratio (ARR) of more than 30 in the presence of PAC
greater than 15 ng/dL and suppressed PRA (<0.5
ng/mL/h), was used as screening test for PA. In the case
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of ARR greater than 30, patient underwent a saline in-
fusion (0.9% NaCl at 500 mL/h) as confirmatory test
and only those with PAC that failed to decreased to less
than 7 ng/dL after the saline infusion were diagnosed as
having PA. In this patient, a computed tomography (CT)
scan or MRI of the adrenal glands or adrenal venous
sampling (AVS) was performed to differentiate between
aldosterone-producing adenoma (APA) from idiopathic
hyperaldosteronism (IHA). The diagnosis of APA was
confirmed by surgery and histological examination.12
Diagnosis of Cushing’s syndrome 
The Cushing’s syndrome (CS) was based on the
clinical signs or symptoms, hormonal data and imaging
tests (pituitary MRI, adrenal CT, adrenal scintigraphy).
Endocrine test for CS showed lack of diurnal
rhythm PC levels (>5 ng/dL), no suppression of PC
(>1.8 ng/dL) levels after a low dose (1 mg dexametha-
sone suppression test) and increased 24 h UFC (>100
μg/24 h). Measurement of plasma adrenocorticotropic
hormone (ACTH) differentiated ACTH-dependent CS
(ACTH >10 pg/mL) from ACTH-independent CS (<10
pg/mL).13
Diagnosis of ACTH-dependent or ACTH-indepen-
dent CS was further confirmed by hypophysis MRI and
abdominal CT or MRI and iodine-norcholesterol
scintigraphy. The final diagnosis of hypophysis or ad-
renal adenoma was confirmed by surgery and histolog-
ical examination.
Diagnosis of pheochromocytoma
The diagnosis of pheochromocytoma (PHEO) was
established on the basis of: i) clinical symptoms; ii) el-
evated value of 24-h urinary metanephrines. Diagnosis
of PHEO was further confirmed by abdominal CT or
MRI scans and 123-iodio-benzilguanidin scintigraphy
and the diagnosis was finally proven by histopatholog-
ical findings of the resected adrenomedullary tumor.14
Statistical analysis
Statistical analysis was performed using the Statis-
tical Package for Social Sciences, version 22.0, statis-
tical software (SPSS, Chicago, IL, USA). Continuous
variables were expressed as mean±standard deviation.
Categorical variables were expressed as frequency dis-
tribution. Possible explanatory variables used as inde-
pendent variable included demographic, clinical, and
ABPM values. Between-group differences in continu-
ous variables were calculated using Student’s t-test.
Fisher’s exact test or χ2 was used in comparison of cat-
egorical variables. A P value <0.05 was considered sig-
nificant.
Results
The study population comprised 3685 consecutive
hypertensive patients (2175 males and 1059 females;
mean age 60.8±14.5 years). In Figure 1, we reported
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Figure 1. Baseline anti-hypertensive drugs in the study population of 3685 patients (2175 males and 1059 females; mean age
60.8±14.5 years; mean drugs taken: 2.2±1.8). MRA, mineralocorticoid receptor antagonist (spironolactone or eplerenone);
CCB, calcium channel blocker; ACE, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
the mean of anti-hypertensive drugs that our hyperten-
sive patients took before the study. In Table 1, we re-
ported the demographic, hemodynamic and biohumoral
parameters of overall 3250 hypertensive patients with
a final diagnosis. 
Of these patients, 232 (5.8%) fulfilled standard cri-
teria of RHT (lifestyle, SBP≥140 mmHg and DBP≥90
mmHg, and use of 3 antihypertensive drugs, one of
them being a diuretic, and comprised the ABPM),5,6 had
a RHT (Figure 2). Ninety-four (40.5%) of these 232
RHT patients were females (mean age 57.38±12.68
years) and 138 (59.5%) were males (mean age
53.457±12.59 years). Ninety-one (39%) patients had
SH (31 females and 61 males; mean age 53.8±12.4
years). Fifty-six (61%) of these patients had PA (16 fe-
males and 40 males; mean age 54.2±12 years). Forty
(71%) of these 56 PA patients (27 males and 13 fe-
males; mean age 55.8±12.4 years) were clinically diag-
nosed as IHA based on bilateral aldosterone
hypersecretion revealed by AVS. Sixteen (29%) PA pa-
tients (13 males and 3 females; mean age 55.8±10.7
years) affected by unilateral hypersecretion of aldos-
terone underwent unilateral laparoscopic adrenalec-
tomy, by expertise surgeons. Histopathological
examinations of the resected adrenal gland confirmed
a diagnosis of APA.
Twenty-two (24.2%) patients had OSA (7 females
and 15 males; mean age 60±10 years). In particular, 8
patients (33%) (5 males and 3 females; mean age
57.6±8.63 years) had severe OSA (apnea-hypopnea
index ≥30), while 16 patients (67%) (12 males and 4
females, mean 61±7 years) had mild OSA (apnea-hy-
popnea index 15-30).
Seven (7.7%) patients had CS (5 females and 2
males; mean age 53.6±11 years). Among these 7 pa-
tients, 5 patients (3 males and 2 females; mean age
52.5±3.5 years) had ACTH-independent CS and under-
went unilateral laparoscopic adrenalectomy; 2 patients
had ACTH-dependent CS and underwent transsphe-
noidal pituitary adenomectomy. The final diagnosis for
adenomas were confirmed by histopathological exam-
inations of the resected specimens.
Five (5.5%) patients had RVH (3 females and 2
males; mean age 43±9.3 years). In these patients, renal
arteriography revealed renal artery stenosis, that was
determined by fibromuscular degeneration in 3 female
patients (mean age 36.7±4 years), and by atheroscle-
rotic changes in other 2 male patients (mean age
52±3.5 years).
One patient (1.1%), a 70-year-old man had adrenal
PHEO, underwent unilateral adrenalectomy and
histopathological exam confirmed the diagnosis of ad-
renal PHEO.
In Table 2, we reported the demographic, hemody-
namic and biohumoral parameters in patients with some
secondary forms of hypertension revealed in RHT pa-
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tients. In particular, we found that the patients with OSA
had major age respect to other patients, associated with
high weight and waist circumference compared to other
groups (P<0.05, respectively). In particular, in Table 3
we reported the ABPM measurements, and we found
that patients with OSA are high global-heart rate values
compared to other groups (P<0.05), and a major per-
centage of non-dipper patterns (P<0.05, respectively).
Discussion
In this study, we aimed to investigate the prevalence
of RHT in a cohort of consecutive hypertensive patients
who were consecutively referred to our Departmental
Unit and we screened for RHT and secondary arterial
hypertension. Our results revealed that in all 3685 con-
secutive hypertensive patients studied, only 232 (5.8%)
patients had a RHT diagnosis. The RHT prevalence can
be considered real because we have used an accurate
enrollment methodology in order to limit and exclude
bias selection. In recent years, is estimated that as many
as 10-15% of the hypertensive population have RHT.4,5
In our study we defined RHT patients only those, other
3 drugs treatment (comprised a diuretic) [sentence not
clear and not linked to the others, please rephrase], and
adherence to life-style changes, with an ABPM that ex-
cluded white coat hypertension,15 still had uncontrolled
BP. In fact, ABPM can be useful to rule out white coat
hypertension if suspected.15
Sometimes, pharmacological BP normalization
could be impossible, due to an inappropriate pharma-
cotherapy or a sub-optimal patient-doctor cooperation.
Poor medication adherence results from the side ef-
fects of antihypertensive drugs, an incomprehensible
dosing regimen, the absence of a subjective feeling of
illness or excessive cost to treatment. Tomaszewski et
al.16 suggest to test patient’s non-adherence by a rou-
tinely detecting by high-performance liquid chro-
matography-tandem mass spectrometry urine analysis
of antihypertensive medications. We did not perform
this test because it was too expensive, thus physician’s
role in patient education still remains of primary im-
portance.
Excessive consumption of sodium, licorice, or al-
cohol is known to increase BP. Many drugs affect BP,
and a trial period of potentially offending medications
may be all that is needed to reduce BP. If these potential
contributors to RHT have been excluded, and concern
for SH still remains, the physician can investigate for
potential pathophysiologic causes. SH represent a very
important contributor to drug-resistance, and may result
in resistance to pharmacologic therapy of hyperten-
sion.17 In fact, 10-20% of these patients may have SH,
in which an underlying, potentially correctable etiology
can be identified.2 Moreover, SH may be a reason for
BP elevation despite comprehensive drug therapy.2
Today, PA, OSA and intrinsic renal disease represent
the most common causes of SH in hypertensive popu-
lation.17 The incidence of SH is unknown, but may be
as high as 10% in newly diagnosed hypertensive pa-
tients. Some authors estimate to be 12.8%, among those
treated with antihypertensive drugs. Furthermore, inad-
equate treatment or poor BP control non-adherence with
both pharmacologic and non-pharmacologic therapy
may lead to overdiagnosis of RHT.17 The systematic
search for secondary causes of hypertension is manda-
tory among patients with RHT, because it includes re-
versible conditions that may help to control BP.
However, the prevalence of SH in RHT patients derived
from studies with several limitations including the sys-
tematic evaluation of secondary forms. In particular, eti-
ology of SH largely depends on studied population,
screening tests applied, confirmatory tests and con-
comitant anti-hypertensive treatment interfering with
adrenal hormones.
In this study we showed that in 232 RHT patients,
91 (39%) had SH. In particular, 56 (61%) patients had
a PA, 22 (24%) had an OSA, 7 (7.7%) had a CS, and 5
(5.5%) had a RVH. Only one patient had adrenal
PHEO. 
These results are consistent with other studies, that
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Figure 2. Prevalence of secondary forms of hypertension in 91 patients with truly resistant hypertension.
also discover large proportions of patients, often re-
ferred from specialist health care, with uncontrolled and
undiscovered SH. Besides, in a tertiary work-up of pa-
tients with apparent RHT (referred for renal denerva-
tion) Heimark and coworkers17 reported that 30 (36%)
patients out of 83, fulfilled the criteria for RHT, and 16
(30%) patients had SH (7 PA, 3 RVH, 3 OSA and 3 with
proteinuria as sign of chronic kidney disease). The pres-
ent study identified in out RHT patients the high preva-
lence of adrenal hypertension (such as PA, CS and
PHEO) followed by OSA and RVH.
PA was considered a rare cause of identifiable or SH
until recently. At today, PA represents the most frequent
form of SH, with a prevalence of more than 11% in
new-onset hypertensive patients.18 The main causes of
PA are bilateral adrenal cortical hyperplasia (IHA) (al-
most 60% of overall cases), and APA (almost 35% of
cases). Rare causes of PA are unilateral adrenal hyper-
plasia (UAH) (2% of cases), and familial hyperaldos-
teronism.12 APA, UAH and aldosterone-producing
adenocarcinoma are treated by surgical approach, IHA
and familial hyperaldosteronism are treated with med-
ications.12
Several studies showed that cardiovascular compli-
cations, such as ischemic heart disease, cerebrovascular
events, arrhythmias (as well as atrial fibrillation) are
more prevalent in PA patients than in essential hyper-
tensive patients, and a specific treatment of aldosterone
excess is associated with long-term benefits.19 There-
fore, several investigators have recommended the
search of PA in all hypertensive patients and in partic-
ular in RHT patients.19
SH is common in CS patients. In fact, large series
comprising a total of more than some hypertensive pa-
tients who have been checked for secondary causes of
hypertension, CS was diagnosed in 1% of them, and
may persist up to 50% patients even several years after
the clinical and humoral remission of their hypercorti-
solism. Besides, the diagnosis of CS-related hyperten-
sion in RHT patients is mandatory.
OSA is a notable cause of SH, particularly in 40-to-
59 years old.20 The standard diagnostic test is
polysomnography, but clinical assessment (e.g., Ep-
worth sleepiness scale, sleep apnea clinical score) with
night-time pulse oximetry may be sufficient for the di-
agnosis of moderate to severe OSA.21 In our study we
showed that the prevalence of OSA in RHT patients
was 22%, and represents in these patients (in percent-
age) the second cause of arterial hypertension, after the
adrenal hypertension. In particular, we showed that
OSA patients had major high weight and waist circum-
ference, and a major percentage of non-dipper profile
at the ABPM compared to other patients with secondary
causes of hypertension.
In patients with OSA the usual variation in BP over
24 h is impaired and it may be beneficial to perform
ABPM on these patients to fully evaluate their circadian
rhythm.
In the literature, there is growing body of evidence
suggesting that non-dipping BP pattern is associated
with a greater risk of target damage among hypertensive
patients.22 The physiopathological cause of this phe-
nomenon resides in the hypoxia and hypercapnia in-
duced by recurrent episodes of airway obstructions
leading to an increased sympathetic neural tone, which
causes vasoconstriction.23 This results in marked in-
creases in BP. Other factors implied in the non-dipper
pattern of hypertension in OSA patients include im-
paired endothelium-dependent vasodilation,23 suffered
NO production,24 oxidative stress,25 and an activation
of the renin-angiotensin-aldosterone system (RAAS).26
In particular, some studies have associated OSA with
excess aldosterone.27 Excess aldosterone leads to edema
of the nasopharyngeal tissues, including tissues in the
upper airway. The mineralocorticoid receptor antagonist
spironolactone, often used add-on anti-hypertensive
therapy, can reduce OSA severity in patients with
RHT.27 Besides, continuous positive airway pressure
therapy to treat OSA down-regulates RAAS compo-
nents and reduces BP.28
Approximately 3-5% of patients with hypertension
have renovascular etiologies. In these patients, renal ar-
tery stenosis results in decreased blood flow to the kid-
neys and activation of the RAAS which in turn
increases systemic BP.29 Atherosclerotic renal artery
stenosis accounts for >90% of cases of renal artery
stenosis. This is most commonly seen in older patients
(>65 years) and is usually associated with atheromatous
disease in other vascular beds. The incidence and preva-
lence are hard to estimate given the asymptomatic na-
ture of the major cases. Less commonly, renal artery
stenosis occurs secondary to fibromuscular dysplasia,
which represents a range of pathologic diagnoses dif-
ferentiated by the layer of the arterial wall that they af-
fect medial fibroplasia is the most prevalent subset of
fibromuscular dysplasia, constituting 75%-80% of all
fibrous lesions of the renal artery [sentence not clear,
please rephrase]. Less common entities include intimal
fibroplasia, perimedial fibroplasia, media hyperplasia,
and adventitial hyperplasia.
Renal artery stenosis is a progressive problem than
can lead to RHT,30 and gradual loss of functional renal
mass resulting in chronic kidney disease. In RHT pa-
tients we found that 5.5% patients have RVH supported
by renal artery stenosis.
In conclusion, to date an exact estimation of RHT
prevalence is not easy, partly due to an inaccurate def-
inition of the problem in scientific research. The use of
ABPM is very important in the identification of white
coat hypertension and non-dipper hypertension. Pa-
tients with RHT may often have identifiable underlying
secondary cause. Adrenal hypertension, OSA and RVH
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are considered to be the most common causes for SH
in RHT patients.
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